AltPep

AltPep Corporation, founded to revolutionize the treatment and diagnosis of amyloid diseases, focuses primarily on Central Nervous System (CNS) disorders like Alzheimer's and Parkinson's Disease. The company's core mission is to identify these diseases long before symptoms manifest and neutralize the toxic soluble oligomers associated with them. Utilizing a proprietary platform based on a library of custom-designed synthetic peptides, AltPep aims to provide early disease-modifying treatments and detection tools, positioning itself at the forefront of biomedical innovation.

Notable figures affiliated with AltPep include leading scientists and industry experts in the field of amyloid diseases. The company has attracted significant interest from investors focused on groundbreaking medical technologies. Key achievements include the development of their synthetic peptide platform and advancements in early detection methods for Alzheimer's and Parkinson's. AltPep's impact lies in its potential to transform the landscape of amyloid disease treatment, offering hope for early intervention and improved patient outcomes in some of the most challenging neurological conditions.